SAB Biotherapeutics (SABS) Receives Buy Rating and $10 Target from H.C. Wainwright | SABS Stock News

Author's Avatar
May 14, 2025

SAB Biotherapeutics (SABS, Financial) has seen a positive development as H.C. Wainwright initiates coverage with a Buy rating and sets a $10 price target. This optimistic outlook follows the release of encouraging results from SAB-142 trials. The trials, conducted on healthy volunteers, revealed durable immunomodulation effects along with a favorable safety profile. These findings suggest that SAB-142, a human anti-thymocyte immunoglobulin, could become a promising new immunotherapy aimed at preventing and managing type 1 diabetes progression.

Wall Street Analysts Forecast

1922608212302000128.png

Based on the one-year price targets offered by 3 analysts, the average target price for SAB Biotherapeutics Inc (SABS, Financial) is $9.00 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies an upside of 379.49% from the current price of $1.88. More detailed estimate data can be found on the SAB Biotherapeutics Inc (SABS) Forecast page.

Based on the consensus recommendation from 4 brokerage firms, SAB Biotherapeutics Inc's (SABS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.